SCHEMBL12373757

SCHEMBL12373757

CCn1c(C(C)NS(=O)(=O)c2cccc3cnccc23)cnc1Oc1ccc(C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 4/20 0.45
PRKD3 O94806 3/20 0.44
PRKCG P05129 3/20 0.44
PRKCB P05771 3/20 0.44
PRKCA P17252 3/20 0.44
PRKCH P24723 3/20 0.44
PRKCI P41743 3/20 0.44
PRKCE Q02156 3/20 0.44
PRKCQ Q04759 3/20 0.44
PRKCZ Q05513 3/20 0.44
PRKCD Q05655 3/20 0.44
PRKD1 Q15139 3/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
NFKB1 P19838 2/20 0.44
GLA P06280 1/20 0.44
LMNA P02545 2/20 0.43
PMP22 Q01453 1/20 0.43
PRKACA P17612 2/20 0.42
PRKACG P22612 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12373511 0.91 PGR (0.42) NR3C1CYP3A4
SCHEMBL12373520 0.84 CASP1 (0.39) CYP3A4CYP2D6LMNAMEN1KMT2A
SCHEMBL12373501 0.83 CYP1A2 (0.41) CYP3A4LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL12373544 0.82 PGR (0.41) NR3C1
SCHEMBL12373551 0.82 CCR4 (0.39) NR3C1
SCHEMBL12373591 0.82 ALDH1A1 (0.38) MEN1KMT2ATP53SMN1; SMN2
SCHEMBL12373547 0.82 PGR (0.40) NR3C1MEN1KMT2A
SCHEMBL12373466 0.82 POLB (0.40) CYP3A4LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL12373769 0.82 S1PR1 (0.45) CYP3A4CYP2D6LMNA
SCHEMBL12373704 0.82 CASP1 (0.45) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE S1PR1, S1PR3, S1PR2 NR3C1 165/4885PRKD3 407/4885PRKCG 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.